OBJECTIVE: To optimize anticoagulation therapy for @entity1211 by means of dabigatran etexilate. MATERIAL AND METHODS: From 2006 to 2012, within the framework of the international trials RE-COVER and RE-COVER II aimed at evaluating efficacy and safety of dabigatran etexilate compared to warfarin, a total of 95 @entity1 meeting the inclusion and exclusion criteria were enrolled in our study. As part of the RE-COVER trial, we carried out analysis of comprehensive examination and treatment of 55 @entity1 with @entity1211 ( @entity1211 ), who were randomly divided into two groups. Group I (Control Group) consisted of 30 @entity1 receiving initial therapy with heparin for seven days followed by taking warfarin for six months. Group II (Study Group) comprised 25 @entity1 taking dabigatran etexilate instead of warfarin. RESULTS: There were no cases of recurrent @entity1211 in the Control Group, and one (4%) @entity1 of the Study Group was found to have a relapse of the disease owing to resistance to anticoagulation therapy and @entity49 . Undesirable events of anticoagulation therapy developed in 20% of the Control Group @entity1 an in 16% of the Study Group @entity1 . In two Control Group @entity1 and one Study Group patient anticoagulation therapy was discontinued due to the development of complications. After 2 years, 36.7% of the Control Group @entity1 and 40% of the Study Group @entity1 had no manifestations of @entity4096 ( @entity4096 ). The degree of @entity4096 was similar in the both groups. CONCLUSION: Dabigatran proved non-inferior to warfarin regarding efficacy, possessing, however, a series of advantages: it has a predictable anticoagulant effect, requires neither monitoring of the haemostasis system, nor dose adjustment, and is administered at standard dosages.

[Optimization of anticoagulation therapy for XXXX .]

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity49 :: ('MESH:D019851', 'Disease') :: ['congenital thrombophilia'] @entity4096 :: ('MESH:D014689', 'Disease') :: ['CVI', 'chronic venous insufficiency']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
